Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis a vaccine 50 u/ml - suspension for injection - 50 u/ml - active: hepatitis a vaccine 50 u/ml excipient: aluminium as amorphous aluminium hydroxyphosphate sulphate borax sodium chloride water for injection - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus. primary immunisation should be given at least 2 weeks prior to expected exposure to hav. vaccination is recommended in children 12 months of age and older, adolescents, and adults who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected, including but not limited to: · travellers to endemic or outbreak areas · frequently affected communities - members residing in any community with one or more recorded outbreaks within the last five years · daycare - children and staff of daycare centres as well as their parents, siblings, and other contacts · military personnel prior to departure for endemic or outbreak areas · persons for whom hepatitis a is an occupational hazard - health-care workers - staff and residents of orphanages, chronic care hospitals and mental health care facilities - sewage workers · haemophiliacs and other recipients of therapeutic blood products · persons who test positive for hepatitis c virus and have diagnosed liver disease · food handlers · consumers of high-risk foods e.g. raw shellfish · persons at increased risk of the disease due to their sexual practices - homosexually-active males - persons who repeatedly contract sexually transmitted diseases · human immunodeficiency virus (hiv)-infected adults · users of illicit injectable drugs vaqta will not prevent hepatitis caused by infectious agents other than hepatitis a virus.

Сингапур - английский - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - water for injection - injection - 0.85 ml - water for injection 0.85 ml

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - live attenuated measles virus; live attenuated rubella virus; live attenuated mumps virus; live attenuated varicella oka strain virus -

Израиль - английский - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hpv type 11 l1 protein; hpv type 16 l1 protein; hpv type 18 l1 protein; hpv type 31 l1 protein; hpv type 33 l1 protein; hpv type 45 l1 protein; hpv type 52 l1 protein; hpv type 58 l1 protein; hpv type 6 l1 protein - suspension for injection - hpv type 58 l1 protein 20 mcg / 0.5 ml; hpv type 52 l1 protein 20 mcg / 0.5 ml; hpv type 45 l1 protein 20 mcg / 0.5 ml; hpv type 33 l1 protein 20 mcg / 0.5 ml; hpv type 31 l1 protein 20 mcg / 0.5 ml; hpv type 18 l1 protein 40 mcg / 0.5 ml; hpv type 16 l1 protein 60 mcg / 0.5 ml; hpv type 11 l1 protein 40 mcg / 0.5 ml; hpv type 6 l1 protein 30 mcg / 0.5 ml - papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) - gardasil 9 is indicated for active immunisation of individuals at the age of 9-45 years old against the following hpv diseases:• premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine hpv types• genital warts (condyloma acuminata) caused by specific hpv types.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - fosaprepitant dimeglumine 197.5mg ((free acid) (120.8 mg)) - powder for injection - 115 mg - active: fosaprepitant dimeglumine 197.5mg ((free acid) (120.8 mg)) excipient: disodium edetate hydrochloric acid lactose polysorbate 80 sodium hydroxide water for injection

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - fosaprepitant dimeglumine 257.6mg ((free acid) (157.5 mg)) - powder for injection - 150 mg - active: fosaprepitant dimeglumine 257.6mg ((free acid) (157.5 mg)) excipient: disodium edetate hydrochloric acid lactose polysorbate 80 sodium hydroxide water for injection - indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: · highly emetogenic cancer chemotherapy · moderately emetogenic cancer chemotherapy in combination with other antiemetic agents.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - cyproheptadine hydrochloride sesquihydrate 4mg;   - tablet - 4 mg - active: cyproheptadine hydrochloride sesquihydrate 4mg   excipient: calcium phosphate lactose monohydrate magnesium stearate maize starch starch

Европейский союз - английский - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

Европейский союз - английский - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

Европейский союз - английский - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.